Armata Pharmaceuticals, Inc.

ARMP

US04216R1023

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:10:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.76 ^USD	+9.06%		+3.56%	-14.81%

Mar. 21	Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M	MT
Mar. 21	Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) added to Russell 3000E Value Index

June 23, 2023 at 12:00 am EDT

Latest news about Armata Pharmaceuticals, Inc.

Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M	Mar. 21	MT
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit	Mar. 04	MT
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference	23-10-30	CI
Armata Pharmaceuticals, Inc. Announces First Patient Dosed in the Phase 2A Portion of the Phase 1b/2a 'Disarm' Study of Ap-Sa02 in Adults with Bacteremia Due to Staphylococcus Aureus	23-09-26	CI
Armata Pharmaceuticals, Inc. Announces CFO Changes	23-09-20	CI
Armata Pharmaceuticals, Inc. Announces Executive Changes	23-09-20	CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Armata Pharmaceuticals, Inc. Announces That It Has Entered into A Credit and Security Agreement with Innoviva Strategic Opportunities Llc	23-07-11	CI
Armata Pharmaceuticals, Inc. Announces Executive Changes	23-07-11	CI
Armata Pharmaceuticals, Inc. Announces Deborah L. Birx to Board of Directors	23-07-11	CI
Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) added to Russell Microcap Value Index	23-06-23	CI
Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) added to Russell 3000E Value Index	23-06-23	CI
Top Premarket Gainers	23-05-18	MT
Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Armata Pharmaceuticals, Inc. Announces Executive Changes	23-05-05	CI
Armata Pharmaceuticals, Inc. Announces Chief Financial Officer Changes	23-05-05	CI
Armata Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-03-15	CI
Top Premarket Gainers	23-03-06	MT
Armata Pharmaceuticals Says Phase 1b/2a Trial of AP-PA02 Shows Drug 'Well-Tolerated' -- Shares Rise Pre-Bell	23-03-06	MT
Armata Pharmaceuticals, Inc. Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis	23-03-06	CI
Armata Pharmaceuticals, Inc. announced that it has received $30 million in funding from Innoviva Strategic Opportunities LLC	23-01-09	CI
Armata Pharmaceuticals Completes Phase 1b/2a Trial of AP-PA02 to Treat Pseudomonas Aeruginosa Infections	22-12-22	MT

Chart Armata Pharmaceuticals, Inc.

Duration

Period

More charts

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Its two lead candidates addresses both chronic and acute bacterial infections. The Company's first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Armata Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.76 USD

Average target price

8 USD

Spread / Average Target

+189.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARMATA PHARMACEUTICALS, INC.	-14.81%	99.77M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research